



## Press Release

### **Preclinical Data on Suven's 5-HT<sub>6</sub> antagonists for CNS diseases to be presented at Neuroscience 2006**

Neuroscience is the annual meeting of **the Society for Neuroscience (SFN)**. More than 30,000 scientists from all over the world will attend this year meeting. **Neuroscience 2006**, the Society's 36th annual meeting, to be held at the Georgia World Congress Center , in Atlanta , GA. , from October 14-18, 2006 . Every year the Society for Neuroscience provides the premier venue for neuroscientists around the world to share their research findings.

Suven will be presenting the **Pre-clinical data of their promising lead compounds, 5-HT<sub>6</sub> antagonists** , highly selective small molecule drug candidates, being developed for the treatment of Mild Cognitive impairment (MCI) associated with Alzheimer's disease or Schizophrenia, Parkinson and Obesity diseases with significant unmet medical need and for which current treatment options are insufficient.

**“We are encouraged by the results of these preclinical studies which lead us to believe that these selected 5HT<sub>6</sub> antagonists may provide a novel, safe and effective approach of treating diseases like MCI, Alzheimer's, Schizophrenia, Parkinson's and obesity”** says Venkat Jasti, **CEO of Suven Life Sciences** . Suven has a number of programs in each of these areas, focusing on novel approaches that may hold promise for the development of new therapies for patients .

## Suven Life Sciences

Suven Life Sciences, a Hyderabad based Indian pharmaceutical company focused on the Drug Discovery and Development of novel, highly selective, potent small-molecule drugs that target G-Protein Coupled Receptors (GPCR's) for the treatment of debilitating Central Nervous System (CNS) disorders such as Alzheimer Disease (AD), Schizophrenia, Depression, Vascular dementia, Mild Cognitive Impairment (MCI), Parkinson's Disease (PD), Memory Impairments with aging, sleep disorders, feeding disorders and obesity.

### **Following is the list of data presentations:**

1. SUVN-507 reverses scopolamine-induced amnesia in Morris water maze and Novel object recognition task.
2. Active metabolite "M1 of SUVN-502": Efficacy profiling in rodent models of cognition.
3. Effect of SUVN-502, Cholinesterase inhibitors in scopolamine induced memory deficit: A comparative study.
4. Morris Water maze task: Incremental increase in dosing of scopolamine increases the sensitivity for screening pro-cognitive drugs.
5. Effect of selective 5-HT<sub>6</sub> receptor antagonists in rodent models of learning

### **Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*